{"Content: ":"IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4] This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.","Title":"IVX-411 - Wikipedia","KeyID":"11169","URL":"https://en.wikipedia.org/wiki/IVX-411"}